Zynerba Pharmaceuticals to Present at the SVB Leerink Global Healthcare Conference
Zynerba Pharmaceuticals (Nasdaq: ZYNE) announced that Armando Anido, its Chairman and CEO, will present a company overview at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 8:40 a.m. ET. The presentation will focus on their innovative transdermal cannabinoid therapies aimed at treating rare neuropsychiatric disorders. Interested investors can arrange virtual meetings or view the presentation via a webcast on the Zynerba website. An archived replay will also be available for 60 days post-event.
- None.
- None.
DEVON, Pa., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will virtually present a company overview during the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 8:40 a.m. ET.
Investors interested in arranging a virtual meeting with the Company’s management during the conference should contact the SVB Leerink conference coordinator. A webcast of the presentation will be available under the Events & Webcasts tab of the Investors section of the Zynerba website at www.zynerba.com. An archived replay will be available on the Company’s website following the event for 60 days.
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, and 22q11.2 deletion syndrome. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Zynerba Contact
Peter Vozzo
ICR Westwicke
Office: 443.213.0505
Cell: 443.377.4767
Peter.Vozzo@Westwicke.com
FAQ
What is Zynerba Pharmaceuticals presenting at the SVB Leerink Global Healthcare Conference on February 18, 2022?
Who will represent Zynerba Pharmaceuticals at the conference on February 18, 2022?
How can investors access Zynerba's presentation at the SVB Leerink Global Healthcare Conference?
Will there be a replay of Zynerba's presentation after the conference?
What therapies does Zynerba Pharmaceuticals focus on?
